mitomycin has been researched along with Purpura, Thrombotic Thrombocytopenic in 10 studies
Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.
Purpura, Thrombotic Thrombocytopenic: An acquired, congenital, or familial disorder caused by PLATELET AGGREGATION with THROMBOSIS in terminal arterioles and capillaries. Clinical features include THROMBOCYTOPENIA; HEMOLYTIC ANEMIA; AZOTEMIA; FEVER; and thrombotic microangiopathy. The classical form also includes neurological symptoms and end-organ damage, such as RENAL FAILURE. Mutations in the ADAMTS13 PROTEIN gene have been identified in familial cases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We examined red cell fragmentation syndrome (RCFS) induced by mitomycin C (MMC) (13 patients), by thrombotic thrombocytopenic purpura (TTP) (17 patients), and by disseminated intravascular coagulation (DIC) (15 patients)." | 7.69 | Hemostatic abnormalities and increased vascular endothelial cell markers in patients with red cell fragmentation syndrome induced by mitomycin C. ( Deguchi, K; Minami, N; Miyanishi, E; Nagaya, S; Oka, K; Tamaki, S; Tanigawa, M; Tsuzi, K; Wada, H; Wakita, Y, 1995) |
| "We examined red cell fragmentation syndrome (RCFS) induced by mitomycin C (MMC) (13 patients), by thrombotic thrombocytopenic purpura (TTP) (17 patients), and by disseminated intravascular coagulation (DIC) (15 patients)." | 3.69 | Hemostatic abnormalities and increased vascular endothelial cell markers in patients with red cell fragmentation syndrome induced by mitomycin C. ( Deguchi, K; Minami, N; Miyanishi, E; Nagaya, S; Oka, K; Tamaki, S; Tanigawa, M; Tsuzi, K; Wada, H; Wakita, Y, 1995) |
| "We examined various markers in 17 patients with thrombotic thrombocytopenic purpura (TTP), 13 with red cell fragmentation syndrome (RCFS) induced by mitomycin C, and 36 with RCFS caused by disseminated intravascular coagulation (DIC)." | 3.69 | [Plasma level of various markers in patients with thrombotic thrombocytopenic purpura]. ( Shirakawa, S; Tamaki, S; Wada, H, 1994) |
| "In this large pooled analysis, we found MMC, when capped at a cumulative dose of 36 mg/m(2), to be safe and tolerable in combination with capecitabine or irinotecan with no reportable cases of TTP/HUS." | 2.46 | Capped-dose mitomycin C: a pooled safety analysis from three prospective clinical trials. ( Arce-Lara, C; Bekaii-Saab, T; Cataland, S; Kraut, E; Ntukidem, N; Otterson, GA, 2010) |
| "Drug-associated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome (TTP/HUS) has been recognized for several years." | 2.43 | Drug-induced thrombotic microangiopathy. ( Bennett, C; Zakarija, A, 2005) |
| "Mitomycin-C (MMC) is a first-line therapy for anal squamous cell carcinoma (ASCC), and it continues to be used for several other indications." | 1.37 | Mitomycin--C-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: cumulative toxicity of an old drug in a new era. ( Chu, E; El-Ghazal, R; Marks, P; Podoltsev, N; Saif, MW, 2011) |
| "Some patients with thrombotic thrombocytopenic purpura (TTP) remain plasma-exchange-dependent for prolonged periods of time." | 1.30 | Splenectomy during partial remission in thrombotic thrombocytopenic purpura with prolonged plasma exchange dependency. ( Bruce, D; Larratt, LM; Mant, MJ; Ritchie, C; Turner, AR, 1999) |
| "We examined 159 patients with thrombotic thrombocytopenic purpura and hemolytic uremic syndrome in Japan." | 1.30 | Outcome of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome in Japan. ( Ihara, T; Kakisita, E; Minami, N; Mori, Y; Omine, M; Shiku, H; Tamaki, S; Wada, H, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (50.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 2 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Onitilo, AA | 1 |
| Engel, JM | 1 |
| Clouse, LH | 1 |
| Gerndt, KM | 1 |
| Ntukidem, N | 1 |
| Arce-Lara, C | 1 |
| Otterson, GA | 1 |
| Kraut, E | 1 |
| Cataland, S | 1 |
| Bekaii-Saab, T | 1 |
| El-Ghazal, R | 1 |
| Podoltsev, N | 1 |
| Marks, P | 1 |
| Chu, E | 1 |
| Saif, MW | 1 |
| Zakarija, A | 1 |
| Bennett, C | 1 |
| Kasper, S | 1 |
| Neurath, MF | 1 |
| Huber, C | 1 |
| Theobald, M | 1 |
| Scharrer, I | 1 |
| Nagaya, S | 2 |
| Wada, H | 4 |
| Oka, K | 1 |
| Tanigawa, M | 1 |
| Tamaki, S | 3 |
| Tsuzi, K | 1 |
| Miyanishi, E | 1 |
| Wakita, Y | 2 |
| Minami, N | 3 |
| Deguchi, K | 1 |
| Kobayashi, M | 1 |
| Shimura, M | 1 |
| Nakase, T | 1 |
| Hiyoyama, K | 1 |
| Nakano, T | 1 |
| Shiku, H | 2 |
| Shirakawa, S | 1 |
| Mant, MJ | 1 |
| Turner, AR | 1 |
| Bruce, D | 1 |
| Ritchie, C | 1 |
| Larratt, LM | 1 |
| Mori, Y | 1 |
| Ihara, T | 1 |
| Omine, M | 1 |
| Kakisita, E | 1 |
2 reviews available for mitomycin and Purpura, Thrombotic Thrombocytopenic
| Article | Year |
|---|---|
Capped-dose mitomycin C: a pooled safety analysis from three prospective clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic | 2010 |
Drug-induced thrombotic microangiopathy.
Topics: ADAM Proteins; ADAMTS13 Protein; Antibiotics, Antineoplastic; Cyclosporine; Endothelium, Vascular; F | 2005 |
8 other studies available for mitomycin and Purpura, Thrombotic Thrombocytopenic
| Article | Year |
|---|---|
Successful treatment of mitomycin-induced thrombotic thrombocytopenic purpura with rituximab.
Topics: Aged; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; F | 2009 |
Mitomycin--C-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: cumulative toxicity of an old drug in a new era.
Topics: Aged; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anus N | 2011 |
Protein A immunoadsorption therapy for refractory, mitomycin C-associated thrombotic microangiopathy.
Topics: Adult; Female; Hemolytic-Uremic Syndrome; Humans; Immunosorbent Techniques; Mitomycin; Purpura, Thro | 2007 |
Hemostatic abnormalities and increased vascular endothelial cell markers in patients with red cell fragmentation syndrome induced by mitomycin C.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Colonic Neoplasms; Cytokines; Disseminated Intravascular | 1995 |
Decreased plasma tissue factor pathway inhibitor levels in patients with thrombotic thrombocytopenic purpura.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Hemolytic; Combined Modality Therapy; Disseminat | 1995 |
[Plasma level of various markers in patients with thrombotic thrombocytopenic purpura].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Hemolytic; Biomarkers; Blood Coagulation Factors | 1994 |
Splenectomy during partial remission in thrombotic thrombocytopenic purpura with prolonged plasma exchange dependency.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Aspirin; Combined Modality Therapy; Erythrocyte Tran | 1999 |
Outcome of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome in Japan.
Topics: Adolescent; Adult; Aged; Aspirin; Bacterial Toxins; Child; Child, Preschool; Clinical Trials as Topi | 1999 |